Q-omics provides the consensus-scored LINC00163 profile across patient tissues and cancer cell-line models. LINC00163 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC00163 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, LINC00163 RNA expression shows 9,800 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, LUAD, and TGCT as cancer lineages where LINC00163 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00163 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00163 survival associations across molecular data types. LINC00163 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00163 RNA expression–survival associations across cancer types. High LINC00163 expression shows unfavorable associations in BRCA, COAD, ACC, LIHC, UCEC and KIRP. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC00163 RNA expression.
This table summarizes LINC00163 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00163. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00163 shows lower tumor expression in LUAD, BLCA, LUSC, BRCA, COAD and READ. The LUAD box plot shows higher LINC00163 RNA expression in normal versus tumor tissue (log2 FC = −1.311, t-test p < 0.001).
This table shows molecular features associated with LINC00163 in patient tissues and cancer cell lines. In patient samples, LINC00163 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
